VITALYST Early Feasibility Study in High-Risk PCI Patients (VITALYST EFS)
Completed · Not applicable · NCT06132568
Conditions: High-risk Percutaneous Coronary Intervention, Heart Disease, Coronary
At a glance
- Research payments reported, 2025
- $80,032
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 15
About the trial
- Sponsor
- Boston Scientific Corporation
- Tested
- VITALYST System (device)
- Dates
- Started 2024-05-09; completion 2025-01-17
- Results posted
- Not yet
The VITALYST Early Feasibility study (EFS) is designed to evaluate the feasibility and safety of the VITALYST System in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).
From ClinicalTrials.gov, last updated 2025-06-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Boston Scientific Corporation reported $80,032 in research payments for this study in 2025 (22 payments).
Products named: Clinical Trial Product
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- David E. Kandzari, MD Interventional Cardiology · Atlanta, GA
- Kevin J. Croce, MD, PHD Cardiology · Chestnut Hill, MA
- Robert W. Yeh, MD Interventional Cardiology · Boston, MA
- Ajay J. Kirtane, M.D., S.M. Interventional Cardiology · New York, NY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Brigham and Women's Hospital, MA $31,056
- Trustees of Columbia Univ in The City of Ny $28,179
- Beth Israel Deaconess Medical Center, MA $14,516
- Piedmont Healthcare $6,281
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.